Kodiak Sciences Announces Upcoming Presentation of KSI-301 Clinical Study Data at American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting and R&D Webinar

Rhea-AI Summary

Kodiak Sciences Inc. (Nasdaq: KOD) announced that new data from the ongoing Phase 1b study of KSI-301, a novel anti-VEGF antibody biopolymer conjugate, will be presented at the ASRS 2020 Virtual Annual Meeting. The presentation will take place on July 10, 2020, showcasing results from 121 patients with wet AMD, diabetic macular edema, and retinal vein occlusion. CEO Victor Perlroth highlighted the promising safety and efficacy data accumulated across over 150 patient-years. A related R&D webinar is set for July 27, 2020, to discuss the implications of these findings.

Positive

• Data presentation from Phase 1b study includes results from nearly 550 injections in 121 patients.
• Demonstrated excellent safety and strong efficacy of KSI-301 in treatment-naïve cohorts.
• Positive indications of durability in treatment outcomes, potentially enhancing market positioning.

Negative

• None.

PALO ALTO, Calif., July 7, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that new data from the ongoing Phase 1b study of KSI-301, its novel anti-VEGF antibody biopolymer conjugate, will be presented at the upcoming American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting.

The presentation is expected to be made available online to ASRS members and meeting attendees via the ASRS Mobile Meeting App on the afternoon of July 10, 2020.  A livestreamed discussion/Q&A panel will be held on Sunday, July 26, 2020, for ASRS Virtual Annual Meeting attendees.

On July 10, 2020, at the time the presentation is released on the ASRS Mobile Meeting App, Kodiak plans to post the slide presentation on the Kodiak Investor Relations website at http://ir.kodiak.com/.

On July 27, 2020, following the livestreamed discussion, Kodiak plans to hold an R&D webinar to discuss the new Phase 1b data and its applicability to Kodiak's ongoing and planned registrational studies for KSI-301.

"We now have over 150 patient-years of experience with KSI-301 across our clinical program, and the Phase 1b data to be presented at ASRS include results from nearly 550 injections in 121 patients with wet AMD, diabetic macular edema, or retinal vein occlusion, many of whom have been followed for a year or longer," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "We have previously announced excellent safety, strong efficacy and remarkable durability with KSI-301 in these treatment-naïve patient cohorts. Over the last six months, the data have continued to mature nicely, and we continue to be highly encouraged by KSI-301's Generation 2.0 anti-VEGF therapeutic profile and the probability of success in our ongoing and forthcoming pivotal studies, which cover all the major indications for anti-VEGF therapy. We look forward to the ASRS presentation and to engaging with the community after the data are released."

Details of the presentation are as follows:

Oral Presentation: One-Year and Beyond: Results of Phase 1b Study of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate with Extended Durability, in wAMD, DME, and RVO
Presenter: Mark Barakat, M.D. -- Retinal Consultants of Arizona, Retinal Research Institute, Phoenix, AZ
Expected Presentation Availability via ASRS Mobile Meeting App: Friday, July 10, 2020 – 4:00 PM Eastern Time.
Virtual Meeting Session: Wet AMD Symposium 3
Virtual Meeting Livestreamed Panel Discussion Date and Time: Sunday, July 26, 2020 – 11:10 AM Eastern Time (open to registered meeting attendees only)

Kodiak plans to issue a press release remarking on the data and to post the slide presentation on the Kodiak Investor Relations website at http://ir.kodiak.com/ at the time the ASRS presentation is released on the ASRS Mobile Meeting App.

Registration details for Kodiak's R&D Webinar planned for July 27, 2020 will be provided closer to the event.

About Kodiak Sciences Inc.

Kodiak (Nasdaq: KOD) is a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases. Founded in 2009, we are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, a leading cause of blindness in elderly patients, and diabetic retinopathy, a leading cause of blindness in working-age patients. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, our bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and we are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA. For more information, please visit -1%26h%3D2023617545%26u%3Dhttp%253A%252F%252Fwww.kodiak.com%252F%26a%3Dwww.kodiak.com&a=www.kodiak.com" rel="nofollow">www.kodiak.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding future development plans and the potential licensure of KSI-301; our platform technology and potential therapies; clinical and regulatory objectives and the timing thereof, anticipated design of planned clinical trials, expectations regarding the potential efficacy and commercial potential of our product candidates; the anticipated presentation of data; the results of our research and development efforts and our ability to advance our product candidates into later stages of development. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "pursue," and other similar expressions among others. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the preliminary safety, efficacy and durability data for our KSI-301 product candidate may not continue or persist; cessation or delay of any of the ongoing clinical studies and/or our development of KSI-301 may occur; future potential regulatory milestones of KSI-301, including those related to current and planned clinical studies may be insufficient to support regulatory submissions or approval; anticipated presentation of data at upcoming conferences may not occur; our research and development efforts and our ability to advance our product candidates into later stages of development may fail; any one or more of our product candidates may not be successfully developed, approved or commercialized; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our most recent Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and Kodiak undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

Kodiak^®, Kodiak Sciences^®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.

 

View original content:http://www.prnewswire.com/news-releases/kodiak-sciences-announces-upcoming-presentation-of-ksi-301-clinical-study-data-at-american-society-of-retina-specialists-asrs-2020-virtual-annual-meeting-and-rd-webinar-301088962.html

SOURCE Kodiak Sciences Inc.

FAQ

What are the results of the KSI-301 Phase 1b study presented on July 10, 2020?

The Phase 1b study results include data from nearly 550 injections across 121 patients, showing significant safety and efficacy.

When will Kodiak Sciences hold the R&D webinar regarding KSI-301?

Kodiak Sciences will hold an R&D webinar on July 27, 2020, to discuss the Phase 1b data and future registrational studies.

What diseases does KSI-301 target?

KSI-301 is designed to treat chronic retinal diseases such as wet AMD, diabetic macular edema, and retinal vein occlusion.

What is the significance of the KSI-301 data presented at the ASRS meeting?

The data highlights promising safety and efficacy results, which are crucial for advancing KSI-301 into pivotal studies.

How can investors access the KSI-301 presentation from the ASRS meeting?

The presentation will be available online on Kodiak's Investor Relations website and through the ASRS Mobile Meeting App on July 10, 2020.